bladder cancer • molecular signalling • therapy • radiosensitization • combination therapy
My research focuses on various aspects of the biology and therapy in bladder cancer. We investigate mechanisms of resistance through combination therapy and develop novel approaches to sensitize bladder cancer to radiotherapy. Experiments include both in vitro and in vivo animal models as well as human bladder tumors.
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W. Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment. PLoS One. 2013 Jun 17;8(6):e65257. doi: 10.1371/journal.pone.0065257.
Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, Netto G, Kassouf W. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol. 2013 Sep;44(9):1766-72.
Mansure JJ, Nassim R, Chevalier S, Szymanski K, Rocha J, Aldousari S, Kassouf W. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS One. 2013;8(2):e55997.
Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian A, Mansure JJ, Kassouf W. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol. 44:95-102, 2013.
Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, and Kassouf W. Inhibition on mammalian target of rapamycin as a therapeutic strategy in bladder cancer. Cancer Biol Ther 8(24):2339-47, 2009.